Who
Kathleen Tregoning
Officer
Company insider
Files Form 4 as: Officer, Kailera Therapeutics; Director, Spero Therapeutics; Director, COMPASS Pathways; Officer, Cerevel Therapeutics Holdings.
In numbers
- Trades disclosed
- 30
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $260K
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 4 Dec 2020
- Last trade
- 6 Jul 2026
- Last filed
- 8 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Jul 2026filed 8 Jul 2026 | KLRA Kailera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 6 Jul 2026filed 8 Jul 2026 | KLRA Kailera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 23 Jun 2026filed 25 Jun 2026 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 23 Jun 2026filed 25 Jun 2026 | SPRO Spero Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 23 Jun 2026filed 25 Jun 2026 | SPRO Spero Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 23 Jun 2026filed 25 Jun 2026 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | CMPS COMPASS Pathwaysoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,119 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | CMPS COMPASS Pathwaysoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,119 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 1 Aug 2024filed 5 Aug 2024 | Cerevel Therapeutics Holdingsoption or derivative | SEC FORM 4 Code D | —614,428 | filing |
| 1 Aug 2024filed 5 Aug 2024 | Cerevel Therapeutics Holdingsoption or derivative | SEC FORM 4 Code D | —59,171 at $0.00 | filing |
| 1 Aug 2024filed 5 Aug 2024 | Cerevel Therapeutics Holdings | SEC FORM 4 Code D | —10,666 | filing |
| 29 May 2024filed 30 May 2024 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 19 Jan 2024filed 23 Jan 2024 | Cerevel Therapeutics Holdingsoption or derivative | SEC FORM 4 Code A | —59,171 at $0.00 | filing |
| 2 Jan 2024filed 4 Jan 2024 | SPRO Spero Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $40K35,604 at $1.12 | filing |
| 26 Dec 2023filed 28 Dec 2023 | Cerevel Therapeutics Holdingsoption or derivative | SEC FORM 4 Code M | —3,150 at $0.00 | filing |
| 26 Dec 2023filed 28 Dec 2023 | Cerevel Therapeutics Holdings | SEC FORM 4 Code M | $32K3,150 at $10.05 | filing |
| 20 Dec 2023filed 21 Dec 2023 | Cerevel Therapeutics Holdings | SEC FORM 4 Sold | $260K6,288 at $41.42 | filing |
| 19 Dec 2023filed 21 Dec 2023 | Cerevel Therapeutics Holdingsoption or derivative | SEC FORM 4 Code M | —13,804 at $0.00 | filing |
| 19 Dec 2023filed 21 Dec 2023 | Cerevel Therapeutics Holdings | SEC FORM 4 Code M | —13,804 | filing |
News
No headline names them, or the companies they trade most, lately.